Nevanimibe

DB16254InvestigationalSmall molecule

Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).

Chemical structure of Nevanimibe
Mechanism
Curator reviewed
Formula / weight
C27H39N3O · 421.629 g/mol (avg)
Also known as
Atr-101 free base
Code names
PD-132301

Resolves to

Compound
UNIIVK9OS8R205CAS133825-80-6ChEMBLCHEMBL46423
Structure
InChIKeyPKKNCEXEVUFFFI-UHFFFAOYSA-NSMILESCC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC1(CCCC1)C1=CC=C(C=C1)N(C)C
Targets
P35610SOAT1O75908SOAT2

What you can answer from here — as of September 20, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Nevanimibe, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In